Navigation Links
FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia
Date:5/6/2009

psychiatrists in treating patients with schizophrenia. It is an effective antipsychotic with excellent tolerability," added Dr. Steven G. Potkin Professor of Psychiatry and Human Behavior at the University of California at Irvine. "We also look forward to Vanda's continuing development of long-acting formulations of Fanapt(TM), to further address the significant unmet medical issues in this population of patients."

"The approval of Fanapt(TM) by the FDA represents many years of tireless efforts by current and former colleagues, many investigators and thousands of patients who participated in the development of this new treatment for schizophrenia. I would like to extend my gratitude to all those who contributed and reaffirm the commitment of Vanda Pharmaceuticals to the discovery and development of medicines for those in need," said Mihael H. Polymeropoulos, MD, Vanda's Chief Executive Officer.

In a 4-week placebo-controlled trial (n=604) involving one fixed dose of Fanapt(TM) (24 mg/day) compared to placebo and an active control (Geodon(R)), the 24 mg/day Fanapt(TM) dose was superior to placebo in the Positive and Negative Syndrome Scale (PANSS) total score.

In a 6-week placebo-controlled trial (n=706) involving two dose ranges of Fanapt(TM) (12-16 mg/day and 20-24 mg/day) compared to placebo and an active control (Risperdal(R)), both doses of Fanapt(TM) were superior to placebo on the Brief Psychiatric Rating Scale (BPRS) total score.

While it is not known how long patients treated with Fanapt(TM) should be maintained on treatment, it is generally recommended that responding patients be continued beyond the acute response. Patients should be periodically reassessed to determine the need for maintenance treatment.

Fanapt(TM) was generally well-tolerated and the most commonly observed adverse reactions (incidence >= 5% and two-fold greater than placebo) were dizzines
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
2. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
3. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
4. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
5. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
6. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
7. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
8. FDA Approves First Hepatitis B Viral Load Test
9. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
10. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
11. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Omeros Corporation (NASDAQ: OMER ) today ... to evaluate OMS824 in Huntington,s disease has been ... (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an ... to a wide range of diseases that affect ... shown promising results in animal models directly relevant ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, Inc., ... today that it will present new results on ... industry conference sponsored by the PML Consortium (composed ... JC polyomavirus (JCV) is the causative agent of ... kinase inhibitor in an extended release formulation, can ...
(Date:5/23/2013)... -- InspireMD, Inc. ("InspireMD" or the ... protection stents, today announced new 6-month results from ... trial demonstrating that the MGuard Embolic Protection Stent ... in all-cause mortality in ST segment elevation myocardial ... presented at the InspireMD STEMI Symposium at EuroPCR, ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... Bionovo, Inc. (Nasdaq: BNVI, BNVID), a drug discovery and development ... oncology, today announced that Dr. Isaac Cohen, O.M.D., Chairman and ... Healthcare Conference at 4:00 p.m. ET on Tuesday, September 28, ... Palace hotel in New York City. Interested parties ...
... Sept. 21 Anthera Pharmaceuticals, Inc. (Nasdaq: ... definitive agreements with certain accredited investors in connection with ... Section 4(2) of the Securities Act of 1933, as ... of the transaction, Anthera will receive gross proceeds of ...
Cached Medicine Technology:Bionovo to Present at the JMP Securities Healthcare Conference 2Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing 2Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing 3Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing 4
(Date:5/23/2013)... Sika Sarnafil , the worldwide market leader in ... Systems of Iowa as the Recycling Project of the ... the re-roofing of the SuperTarget retail store in Olathe, ... contractor and one of Target’s Preferred Tier One roofing ... building practices and they are a worthy recipient of ...
(Date:5/23/2013)... Professional Insurance Plans, an independent insurance ... celebrate Fibromyalgia Education and Awareness Month. As a ... country, the agency feels that it is important for ... that affects an estimated 10 million of Americans. , ... definition of Fibromyalgia (FM) is, “a common and complex ...
(Date:5/23/2013)... 23, 2013 Traditionally, laser skin therapy ... on skins of colour, this can be tricky. Based ... 1-1V may be treated safely with most lasers. Darker ... discoloration issues, have been left without recourse. Those who ... “clear” their skin successfully. , Hyperpigmentation occurs ...
(Date:5/23/2013)... , , THURSDAY, May 23 (HealthDay News) -- Statins are ... but the medications also could hamper heart patients, ability ... A small group of overweight or obese people ... taking a 40 milligram daily dose of simvastatin, while ... same exercise regimen did show improvement, found the study ...
(Date:5/23/2013)... PTSD , Soldiers returning home from combat may ... disorder if public support for a war effort is ... shapes the level of distress soldiers feel from the ... two experiments that asked participants to exterminate woodlice in ... actor show either interest or disgust for the act ...
Breaking Medicine News(10 mins):Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2Health News:Vancouver Skin Care Clinic Successfully Clears Pigmentation in Skin of Colour 2Health News:Vancouver Skin Care Clinic Successfully Clears Pigmentation in Skin of Colour 3Health News:Statins May Hamper Workout Results 2Health News:Statins May Hamper Workout Results 3Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 2Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 3
... Spanish . , The PhD, defended ... the Basque Country, proposes a series of recommendations that ... professionals who treat terminal cancer patients. , Autonomy is ... armed with knowledge about the causes of the illness, ...
... talk and ... care about digestive health, WHITE PLAINS, ... advertising campaign for Activia featuring award-winning,actress and passionate self-esteem advocate ... air throughout 2008, Curtis draws attention,to the importance of digestive ...
... Named National, Spokesperson for The Leukemia & Lymphoma Society,s 2008 Light The ... ... March 3 Rob Brown, who stars in the,upcoming drama The Express as ... to win the Heisman,Trophy, is the national spokesperson for The Leukemia & Lymphoma ...
... The Providence Service,Corporation (Nasdaq: PRSC ) today ... its fourth quarter and year ended December 31, 2007,on ... Providence will hold a conference call at 11:00 a.m. ... Thursday, March 13, 2008 to discuss its,financial results and ...
... CEL-SCI CORPORATION,(Amex: CVM ) provided details ... groundbreaking activities currently underway at its,manufacturing facility near ... Multikine(R), the Company,s lead compound, for a pivotal,Phase ... untreated head,and neck cancer patients. The facility, which ...
... ... Hospitals, TEL AVIV, ... digital templating software, will,launch its unique Orthoweb on-line service at the ... in San,Francisco (Booth #349, Hall A)., "This is a real ...
Cached Medicine News:Health News:Factors that enhance autonomy of cancer patients 2Health News:Factors that enhance autonomy of cancer patients 3Health News:Dannon Activia Launches Thought-Provoking Advertising Campaign Featuring Jamie Lee Curtis 2Health News:Dannon Activia Launches Thought-Provoking Advertising Campaign Featuring Jamie Lee Curtis 3Health News:Actor Rob Brown Rushes to Gain Ground Against Blood Cancer 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 3Health News:CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial 2Health News:Orthocrat to Launch On-Line Service for Storing and Sharing Pre-Operative Data at AAOS 2
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... coated with a thin layer ... the surface slick as glass ... prevent debris from collecting on ... For partial stenosis. Silicone with ...
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Medicine Products: